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Results: First, we identified that specific inhibition of PI4K 
IIIα using RNAi increased radiosensitivity in the human cancer 
cell lines we tested. In contrast, inhibition of other isotypes 
did not affect a radiosensitivity of these cancer cell lines. 
Next, in vitro kinase assays showed, simeprevir, a selected 
anti-HCV agent via IC50 assay, inhibited activity of PI4K IIIα in 
a dose-response manner. Pretreatment of simeprevir induced 
discernible downregulation of p-PKC and p-Akt and also 
increased clonogenic survival of U251, BT474, and HepG2 
cells in vitro and also significantly delayed growth of mouse 
tumor xenografts in vivo. Simeprevir caused prolongation of 
γH2AX foci after irradiation, decreased invasion / migration 
and downregulation of PD-L1 expression. 
 
Conclusion: Targeting PI4K IIIα using anti-HCV agent could be 
a viable drug repositioning approach to enhance the 
therapeutic efficacy of radiotherapy for breast cancer, 
glioblastoma and hepatoma. (Work supported by grant 
#2013R1A1A2074531 from the Ministry of Science, ICT & 
Future Planning to Kim IA) 
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Purpose or Objective: To investigate serial changes of tumor 
hypoxia in response to a single high dose irradiation by 
various clinical and pre-clinical methods in order to propose 
an optimal fractionation schedule for stereotactic ablative 
radiotherapy (SABR) 
 
Material and Methods: Syngeneic Lewis lung carcinomas 
were grown either orthotopically or subcutaneously in 
C57BL/6 mice and were irradiated with a single dose of 15 Gy 
to mimic SABR used in the clinic. Serial [18F]-misonidazole 
(F-MISO) positron emission tomography (PET) imaging, 
pimonidazole FACS analyses, hypoxia-responsive element 
(HRE)-driven bioluminescence, and Hoechst 33342 perfusion 
were performed before irradiation (d-1), at 6 hours (d0), 2 
(d2), and 6 days (d6) after irradiation for both subcutaneous 
and orthotopic lung tumors. For F-MISO, scan was performed 
2 hr after the intravenous injection of F-MISO probe and the 
tumor-to-brain ratio (TBR) was analyzed.  
 
Results: We observed that hypoxic signals were too low to 
quantitate for orthotopic tumors by F-MISO PET or HRE-driven 
bioluminescence imaging. In subcutaneous tumors TBR values 
were 2.87 ± 0.483 at d-1, 1.67 ± 0.116 at d0, 2.92 ± 0.334 at 
d2, and 2.13 ± 0.385 at d6, indicating that tumor hypoxia was 
decreased immediately after irradiation and returned to the 
pretreatment levels at d2, followed by a slight decrease by 
d6 post-radiation. Pimonidazole analysis also revealed similar 
patterns. By using Hoechst 33342 vascular perfusion dye and 
CD31 co-immunostaining, we found that there was a rapid 
and transient vascular collapse, which may have resulted in 
poor intratumoral perfusion of F-MISO PET tracer or 
pimonidazole delivered at d0 leading to decreased hypoxic 




Fig. 1. Temporal changes in tumor hypoxia for subcutaneous 
tumors by F-MISO PET imaging. (A) Representative PET 
images demonstrating F-MISO uptake in subcutaneous tumor. 
Arrows indicate the tumor position. (B) A graph showing TBR 
values for an individual animal. (C) A graph showing the mean 
± s.e.m. of TBR values (n = 5).  
 
Conclusion: We found tumor hypoxia levels to be returned to 
the pretreatment levels by 2 days after irradiation, hence 
supporting the current fractionation intervals of SABR being 
given at least 2 days. Our results also indicate that SABR may 
produce a rapid but reversible vascular collapse in tumors. 
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Purpose or Objective: In previous study we showed that 
γH2AX assay in ex vivo irradiated tumour samples collected 
from cancer patients of various types correlates with known 
differences in radioresponsiveness. In the present study we 
aimed to apply the assay in a panel of prostate tumour 
